首页|Functional lineage tracing to study the clonal evolution of therapy resistance
Functional lineage tracing to study the clonal evolution of therapy resistance
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Despite many significant advances in cancer therapies, resistance still remains a critical problem preventing durable responses and complete cures. While it is important to dissect the molecular mechanisms of therapy resistance, understanding how resistance evolves can unveil additional therapeutic opportunities. A key question is if resistance is pre-existing in a rare sub-fraction of cancer cell clones or obtained by some cancer cell clones only upon treatment. This knowledge could dictate which therapeutic strategy to pursue: specifically targeting the pre-existing relevant subfraction with a second drug in a combination treatment or targeting the relevant mechanism that allows adaptation to the primary treatment. To assess if a resistant clone was inherently resistant or adapted under treatment, the treatment-naive condition needs to be investigated. However, these clones can be particularly rare, and finding them in a complex cancer cell population is challenging. Classical sequencing approaches lack the necessary resolution, and conventional DNA barcoding experiments only allow indirect conclusions.
Christian Umkehrer
展开 >
Cancer Cell Signaling, Boehringer-Ingelheim RCV GmbH & Co KG, Vienna, Austria.
NSTL
